Page last updated: 2024-12-09

potassium oxonate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

potassium oxonate: used to induce hyperuricemia in mice [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2723920
CHEMBL ID3184847
CHEBI ID80230
SCHEMBL ID339417
MeSH IDM0472237

Synonyms (64)

Synonym
AC-2039
NSC28841 ,
allantoxanic acid potassium salt
oxonic acid, potassium salt
potassium 2,6-dihydroxytriazinecarboxylate
2207-75-2
nsc-28841
potassium azaorotate
potassium oxonate
allantoxanic acid, potassium salt
allantoxanic acid, monopotassium salt
oxonate
oxonate, potassium
1,3,5-triazine-2-carboxylic acid, 1,4,5,6-tetrahydro-4,6-dioxo-, monopotassium salt
einecs 218-627-5
5-azaorotic acid, potassium salt
1,4,5,6-tetrahydro-4,6-dioxo-s-triazine-2-carboxylic acid, potassium salt
potassium s-triazine-2,4-dione-6-carboxylate
potassium 1,4,5,6-tetrahydro-4,6-dioxo-1,3,5-triazine-2-carboxylate
nsc 28841
oteracil potassium
NCGC00166236-01
potassium allantoxanate
O0164
oxonic acid potassium salt
potassium 4,6-dihydroxy-1,3,5-triazine-2-carboxylate
potassium 4,6-dioxo-1h-1,3,5-triazine-2-carboxylate
tox21_112362
dtxsid5046568 ,
dtxcid3026568
cas-2207-75-2
AKOS006229816
potassium 4,6-dioxo-1,4,5,6-tetrahydro-1,3,5-triazine-2-carboxylate
AKOS015964230
AKOS015961942
unii-4r7ffa00rx
4r7ffa00rx ,
FT-0603597
s-1 component oteracil potassium
oteracil potassium [who-dd]
teysuno component oteracil potassium
oteracil potassium component of teysuno
oteracil potassium [jan]
HY-17511
SCHEMBL339417
CHEBI:80230 ,
potassiumoxonate
Q-100280
CHEMBL3184847
AKOS025116606
mfcd00010565
oxonic acid (potassium salt)
5-azaoroticacid,potassiumsalt
SY036250
IAPCTXZQXAVYNG-UHFFFAOYSA-M
BCP06172
Q27149343
F14898
AS-13301
AMY40569
potassium otastat
potassium;4,6-dioxo-1h-1,3,5-triazine-2-carboxylate
EN300-1708017
Z3066893590

Research Excerpts

Treatment

Potassium oxonate-treated tree shrews may be a potential animal model for studying pathogenic mechanism and evaluating a new therapeutic agent for treatment of HUA in humans.

ExcerptReferenceRelevance
"In potassium oxonate-treated rats, treatment with uricosuric agents such as FYU-981, F12859 and probenecid showed no hypouricemic effect. "( Uricosuric agents decrease the plasma urate level in rats by concomitant treatment with topiroxostat, a novel xanthine oxidoreductase inhibitor.
Ashizawa, N; Iwanaga, T; Matsumoto, K; Saitoh, K; Taniguchi, T, 2016
)
1.06
"Potassium oxonate-treated tree shrews may be a potential animal model for studying pathogenic mechanism and evaluating a new therapeutic agent for treatment of HUA in humans."( Potassium oxonate induces acute hyperuricemia in the tree shrew (tupaia belangeri chinensis).
Li, ZL; Ma, KL; Tang, DH; Wang, CY; Ye, YS; Zheng, H, 2017
)
2.62

Toxicity

ExcerptReferenceRelevance
" Major adverse effects were hematological toxicities, gastrointestinal disturbance, neurosensory toxicity."( [Efficacy and side effects of combination therapy of oxaliplatin and S-1 for colorectal cancer].
Jin, ZM; Zhu, QC, 2011
)
0.37
" Future studies should consider uric acid together with melamine when examining adverse effects in humans."( Melamine Nephrotoxicity is Mediated by Hyperuricemia.
Li, HT; Liu, JM; Trachtman, H; Trasande, L; Wang, LL; Wang, PX; Zhang, L, 2015
)
0.42
" In respect of adverse events, both the rates of hematological and non-hematological toxicities were low and similar between the two groups (P>0."( [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Hui, H; Sun, S; Wan, Y; Wang, X; Wu, J, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic parameters of tegafur, 5-fluorouracil, gimeracil, potassium oxonate and uracil after single oral administration were as follows: (2,207 +/- 545), (220."( [Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
Chu, Y; Ding, L; Liu, HY; Yu, Y; Zhu, H, 2012
)
0.61
" Pharmacokinetic parameters, including Cmax, Tmax, t1/2, AUC0-t, and AUC0-∞ were determined using non-compartmental models with DAS2."( Pharmacokinetic evaluation of novel oral fluorouracil antitumor drug S-1 in Chinese cancer patients.
Bian, HH; Chen, L; Pu, WY; Wang, H; Wang, J; Zhang, H; Zhu, H; Zhu, MG; Zhuang, ZX, 2013
)
0.39

Compound-Compound Interactions

ExcerptReferenceRelevance
"To determine the clinical toxicities and antitumor effects of a chemotherapy regimen of FTQ, a compound preparation of tegafur, the drug prototype of 5-furacil (5-FU), gimeracil (CDHP), a decomposition inhibitor of 5-FU, oteracil potassium, phosphorylation inhibitor of 5-FU, and combined with cisplatin in patients with inoperable locally or metastatic advanced gastric cancer."( [Curative effects of FTQ combined with cisplatin in treatment of advanced gastric cancer: a multicenter study].
Dai, GH; Jiao, SC; Li, F; Li, Y; Liu, W; Lu, HS; Niu, RG; Song, SP; Wang, J; Xie, XD; Xu, JM; Yang, JL; Zhang, FC; Zhang, Y; Zhao, H, 2008
)
0.35
"The regimen of FTQ combined with cisplatin is generally well-tolerated and has substantial antitumor activity."( [Curative effects of FTQ combined with cisplatin in treatment of advanced gastric cancer: a multicenter study].
Dai, GH; Jiao, SC; Li, F; Li, Y; Liu, W; Lu, HS; Niu, RG; Song, SP; Wang, J; Xie, XD; Xu, JM; Yang, JL; Zhang, FC; Zhang, Y; Zhao, H, 2008
)
0.35
"To observe the efficacy and safety of chemotherapy regimens oxaliplatin combined with capecitabine (CAPOX) or oxaliplatin combined with tegafur, gimeracil and oteracil potassium capsules (S-1)(SOX), and to investigate the value of expression of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) proteins in tumor tissue for predicting the efficacy of CAPOX and SOX regimens in advanced gastric cancer patients."( [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Hui, H; Sun, S; Wan, Y; Wang, X; Wu, J, 2016
)
0.43
" The expression levels of TP and DPD in tumor tissue can be used as a predictive factor for the efficacy of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin regimens."( [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Hui, H; Sun, S; Wan, Y; Wang, X; Wu, J, 2016
)
0.43
"01); and suggested WECM may interact with URAT1."( Actions of water extract from Cordyceps militaris in hyperuricemic mice induced by potassium oxonate combined with hypoxanthine.
Chen, D; Chen, S; Feng, D; Jiao, C; Shuai, O; Su, J; Xie, Y; Yong, T; Zhang, M, 2016
)
0.66

Bioavailability

ExcerptReferenceRelevance
" According to ADME (absorption, distribution, metabolism, and excretion) simulation in silico, flazin had good oral bioavailability in vivo."( Effect of Soy Sauce on Serum Uric Acid Levels in Hyperuricemic Rats and Identification of Flazin as a Potent Xanthine Oxidase Inhibitor.
Li, H; Lin, L; Su, G; Wang, Y; Zhao, M, 2016
)
0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" In this study, we used glucosyl hesperidin (GH), which has greater bioavailability than hesperidin, to clarify comprehensive mechanisms underlying the hypouricemic effects of hesperidin in vivo."( Comprehensive analysis of mechanism underlying hypouricemic effect of glucosyl hesperidin.
Harada-Shiba, M; Hirata, H; Ogura, M; Ota-Kontani, A; Tsuchiya, Y, 2020
)
0.56
" However, the relatively low oral bioavailability of Sco limits its further applications."( Antihyperuricemic efficacy of Scopoletin-loaded Soluplus micelles in yeast extract/potassium oxonate-induced hyperuricemic mice.
Ma, Y; Mao, J; Yang, Z; Zeng, Y; Zheng, Y, 2020
)
0.78
" However, BBR exhibits low bioavailability due to its extensive metabolism and limited absorption."( Berberrubine attenuates potassium oxonate- and hypoxanthine-induced hyperuricemia by regulating urate transporters and JAK2/STAT3 signaling pathway.
Chen, J; Huang, Z; Jiang, L; Li, Y; Lin, G; Lin, Z; Liu, Y; Mai, L; Su, Z; Xie, J; Xu, L; Yu, Q, 2021
)
0.93

Dosage Studied

Potassium oxonate-induced hyperuricemic mice were dosed by gavage with eight stilbenes. serum uric acid level was measured after 3 h of administration.

ExcerptRelevanceReference
" All treatments at the same dosage (100 mmol/kg) were administered to the abdominal cavity of PO-induced hyperuricemic mice, and serum uric acid level was measured at 3 h after administration."( Phytochemicals from Acacia confusa heartwood extracts reduce serum uric acid levels in oxonate-induced mice: their potential use as xanthine oxidase inhibitors.
Chang, ST; Chen, CS; Hsu, CA; Huang, CC; Tung, YT; Yang, SC, 2010
)
0.36
"Potassium oxonate-induced hyperuricemic mice were dosed by gavage with eight stilbenes."( Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice.
Hong, Y; Kong, LD; Li, Z; Liu, L; Liu, YL; Shi, YW; Wang, CP; Wang, X, 2012
)
1.82
" In addition, the four major bioactive phytochemicals at the same dosage (100 mmol/kg) were administered to the abdominal cavity of potassium oxonate (PO)-induced hyperuricemic mice, and the serum uric acid level was measured after 3 h of administration."( Antioxidative phytochemicals from Rhododendron oldhamii Maxim. leaf extracts reduce serum uric acid levels in potassium oxonate-induced hyperuricemic mice.
Chiu, CC; Chuang, HL; Ho, ST; Huang, CC; Lin, CY; Lin, LC; Liu, YL; Tung, YT; Wu, JH, 2015
)
0.83
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (132)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's17 (12.88)29.6817
2010's79 (59.85)24.3611
2020's36 (27.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.39 (24.57)
Research Supply Index4.94 (2.92)
Research Growth Index5.14 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (5.30%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other125 (94.70%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]